High S100A2 expression in keratinocytes in patients with drug eruption

Abstract Telaprevir used as a protease inhibitor against hepatitis C virus is frequently associated with cutaneous adverse reactions. To explore a histological biomarker of cutaneous adverse events induced by telaprevir, we systematically searched for genes that were dysregulated by telaprevir in no...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Manabu Yoshioka, Yu Sawada, Natsuko Saito-Sasaki, Haruna Yoshioka, Kayo Hama, Daisuke Omoto, Shun Ohmori, Etsuko Okada, Motonobu Nakamura
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7e6e44df5970471eb134e6fe688c8ff4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7e6e44df5970471eb134e6fe688c8ff4
record_format	dspace
spelling	oai:doaj.org-article:7e6e44df5970471eb134e6fe688c8ff42021-12-02T11:37:26ZHigh S100A2 expression in keratinocytes in patients with drug eruption10.1038/s41598-021-85009-82045-2322https://doaj.org/article/7e6e44df5970471eb134e6fe688c8ff42021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85009-8https://doaj.org/toc/2045-2322Abstract Telaprevir used as a protease inhibitor against hepatitis C virus is frequently associated with cutaneous adverse reactions. To explore a histological biomarker of cutaneous adverse events induced by telaprevir, we systematically searched for genes that were dysregulated by telaprevir in normal human epidermal keratinocytes (NHEKs). Microarray analysis and real-time polymerase chain reaction (PCR) revealed the significant increase in the expression of S100 calcium-binding protein A2 (S100A2) gene following treatment of NHEKs with telaprevir. Immunohistochemical analysis demonstrated that the expression of S100A2 was dominant in the spinous layer of the epidermis in patients with telaprevir-mediated severe-type drug eruptions and limited to the basal layer of the epidermis in healthy subjects. Furthermore, S100A2 expression increased after treatment with trichloroethylene and other medications, and the degree of S100A2 expression correlated with the severity of cutaneous adverse events. S100A2 expression also significantly increased in the skin of patients with atopic dermatitis and psoriasis. Taken together, S100A2 is highly expressed in the epidermis under inflammatory conditions and drug eruptions and may serve as a marker for keratinocyte damage in response to any inflammatory or toxic condition.Manabu YoshiokaYu SawadaNatsuko Saito-SasakiHaruna YoshiokaKayo HamaDaisuke OmotoShun OhmoriEtsuko OkadaMotonobu NakamuraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Manabu Yoshioka Yu Sawada Natsuko Saito-Sasaki Haruna Yoshioka Kayo Hama Daisuke Omoto Shun Ohmori Etsuko Okada Motonobu Nakamura High S100A2 expression in keratinocytes in patients with drug eruption
description	Abstract Telaprevir used as a protease inhibitor against hepatitis C virus is frequently associated with cutaneous adverse reactions. To explore a histological biomarker of cutaneous adverse events induced by telaprevir, we systematically searched for genes that were dysregulated by telaprevir in normal human epidermal keratinocytes (NHEKs). Microarray analysis and real-time polymerase chain reaction (PCR) revealed the significant increase in the expression of S100 calcium-binding protein A2 (S100A2) gene following treatment of NHEKs with telaprevir. Immunohistochemical analysis demonstrated that the expression of S100A2 was dominant in the spinous layer of the epidermis in patients with telaprevir-mediated severe-type drug eruptions and limited to the basal layer of the epidermis in healthy subjects. Furthermore, S100A2 expression increased after treatment with trichloroethylene and other medications, and the degree of S100A2 expression correlated with the severity of cutaneous adverse events. S100A2 expression also significantly increased in the skin of patients with atopic dermatitis and psoriasis. Taken together, S100A2 is highly expressed in the epidermis under inflammatory conditions and drug eruptions and may serve as a marker for keratinocyte damage in response to any inflammatory or toxic condition.
format	article
author	Manabu Yoshioka Yu Sawada Natsuko Saito-Sasaki Haruna Yoshioka Kayo Hama Daisuke Omoto Shun Ohmori Etsuko Okada Motonobu Nakamura
author_facet	Manabu Yoshioka Yu Sawada Natsuko Saito-Sasaki Haruna Yoshioka Kayo Hama Daisuke Omoto Shun Ohmori Etsuko Okada Motonobu Nakamura
author_sort	Manabu Yoshioka
title	High S100A2 expression in keratinocytes in patients with drug eruption
title_short	High S100A2 expression in keratinocytes in patients with drug eruption
title_full	High S100A2 expression in keratinocytes in patients with drug eruption
title_fullStr	High S100A2 expression in keratinocytes in patients with drug eruption
title_full_unstemmed	High S100A2 expression in keratinocytes in patients with drug eruption
title_sort	high s100a2 expression in keratinocytes in patients with drug eruption
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7e6e44df5970471eb134e6fe688c8ff4
work_keys_str_mv	AT manabuyoshioka highs100a2expressioninkeratinocytesinpatientswithdrugeruption AT yusawada highs100a2expressioninkeratinocytesinpatientswithdrugeruption AT natsukosaitosasaki highs100a2expressioninkeratinocytesinpatientswithdrugeruption AT harunayoshioka highs100a2expressioninkeratinocytesinpatientswithdrugeruption AT kayohama highs100a2expressioninkeratinocytesinpatientswithdrugeruption AT daisukeomoto highs100a2expressioninkeratinocytesinpatientswithdrugeruption AT shunohmori highs100a2expressioninkeratinocytesinpatientswithdrugeruption AT etsukookada highs100a2expressioninkeratinocytesinpatientswithdrugeruption AT motonobunakamura highs100a2expressioninkeratinocytesinpatientswithdrugeruption
_version_	1718395769142116352

High S100A2 expression in keratinocytes in patients with drug eruption

Ejemplares similares